Advertisement
Advertisement
U.S. Markets open in 5 hrs 3 mins
Advertisement
Advertisement
Advertisement
Advertisement

VectivBio Holding AG (VECT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.03+0.41 (+8.98%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.62
Open4.91
Bid0.00 x 900
Ask0.00 x 1200
Day's Range4.85 - 5.03
52 Week Range2.74 - 8.15
Volume1,038
Avg. Volume11,866
Market Cap180.565M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.58
Earnings DateNov 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.20
  • GlobeNewswire

    Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

    $5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2022, and provided a clinical and business update. High

  • GlobeNewswire

    VectivBio Announces Closing of $54 Million Aggregate Financing

    BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced public offering of 6,467,688 ordinary shares, including the sale to the underwriters of 752,688 ordinary shares sold pursuant to the partial exercise of the underwriters’ previously granted option to purchase additional or

  • GlobeNewswire

    VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares

    Combined Gross Proceeds from Public Offering and Private Sale Total $50 MillionBASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of a follow-on public offering of 5,715,000 ordinary shares at a public offering price of $5.25 per share for aggregate gross proceeds of approximately $30 million, before

Advertisement
Advertisement